iShares U.S. Medical Devices ETF IHI

iShares U.S. Medical Devices ETF (el Fondo), anteriormente conocido como iShares Dow Jones U.S. Medical Devices Index Fund, es un fondo cotizado en bolsa (ETF). El Fondo busca resultados de inversión que se correspondan generalmente con el rendimiento del precio y el rendimiento de los dividendos del Dow Jones U.S. Select Medical Equipment Index (el Índice). El Índice mide el rendimiento del sector de equipos médicos del mercado de valores de Estados Unidos e incluye empresas de equipos médicos, como fabricantes y distribuidores de dispositivos médicos, como resonancias magnéticas (MRI), prótesis, marcapasos, máquinas de rayos X y otros dispositivos médicos no desechables. El Fondo invierte en una muestra representativa de valores incluidos en el Índice que colectivamente tienen un perfil de inversión similar al Índice. El asesor de inversiones del Fondo es BlackRock Fund Advisors.

Con 20 acciones de IHI (USD 1.007,50) habrías recibido USD 5,20 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 sept

  Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

  The iShares U.S. Medical Devices ETF (IHI) is reviewed as a passively managed fund offering diversified exposure to the healthcare medical devices sector. With $3.44 billion in assets and a 0.37% expense ratio, IHI tracks the Dow Jones U.S. Select Medical Equipment Index. The fund has declined 12.46% year-to-date and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable but not exceptional choice for sector exposure.

  

• Benzinga 15 ene

  Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026

  Becton, Dickinson and Company received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, with market launch expected in early 2026. The advanced system features high and low vacuum strengths, 360-degree sampling ability, and multiple probe options. However, analysts expect slightly lower earnings and revenue compared to the prior year quarter, and the stock is considered overvalued despite a consensus Buy rating.

  

• Benzinga 15 ene

  Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy

  Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-24% revenue growth. Boston Scientific expects 6-8 cents per share dilution in year one, trending toward neutral to accretive thereafter. The deal is expected to close in 2026.

  

• Benzinga 8 jul

  Samsung's Xealth Acquisition Connects Patient Data To Clinical Care

  Samsung Electronics plans to acquire Xealth, a digital health platform, to integrate wearable device data with hospital systems, enhancing personalized healthcare and advancing its digital health strategy.

  

• Zacks Investment Research 24 jun

  Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

  Sector ETF report for XHE